BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 15326109)

  • 21. Urokinase-type plasminogen activator negatively regulates α-smooth muscle actin expression via Endo180 and the uPA receptor in corneal fibroblasts.
    Sugioka K; Nishida T; Kodama-Takahashi A; Murakami J; Mano F; Okada K; Fukuda M; Kusaka S
    Am J Physiol Cell Physiol; 2022 Jul; 323(1):C104-C115. PubMed ID: 35649252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction.
    Yebra M; Goretzki L; Pfeifer M; Mueller BM
    Exp Cell Res; 1999 Jul; 250(1):231-40. PubMed ID: 10388537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.
    Nordengren J; Pilka R; Noskova V; Ehinger A; Domanski H; Andersson C; Høyer-Hansen G; Hansson SR; Casslén B
    Mol Hum Reprod; 2004 Sep; 10(9):655-63. PubMed ID: 15243126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of the receptor for the human urokinase-type plasminogen activator using fluoresceinated uPA.
    Ciccocioppo R; Capri MG; Alberti S
    J Histochem Cytochem; 1997 Sep; 45(9):1307-13. PubMed ID: 9283618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Convergence of the adhesive and fibrinolytic systems: recognition of urokinase by integrin alpha Mbeta 2 as well as by the urokinase receptor regulates cell adhesion and migration.
    Pluskota E; Soloviev DA; Plow EF
    Blood; 2003 Feb; 101(4):1582-90. PubMed ID: 12393547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
    Vines DJ; Lee SW; Dichek DA; Ellis V
    J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
    Mahanivong C; Yu J; Huang S
    Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Localization of urokinase type plasminogen activator to focal adhesions requires ligation of vitronectin integrin receptors.
    Wilcox-Adelman SA; Wilkins-Port CE; McKeown-Longo PJ
    Cell Adhes Commun; 2000; 7(6):477-90. PubMed ID: 11051458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urokinase-induced mitogenesis is mediated by casein kinase 2 and nucleolin.
    Dumler I; Stepanova V; Jerke U; Mayboroda OA; Vogel F; Bouvet P; Tkachuk V; Haller H; Gulba DC
    Curr Biol; 1999 Dec 16-30; 9(24):1468-76. PubMed ID: 10607589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell-surface acceleration of urokinase-catalyzed receptor cleavage.
    Høyer-Hansen G; Ploug M; Behrendt N; Rønne E; Danø K
    Eur J Biochem; 1997 Jan; 243(1-2):21-6. PubMed ID: 9030717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
    Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
    BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urokinase-type plasminogen activator promotes dendritic spine recovery and improves neurological outcome following ischemic stroke.
    Wu F; Catano M; Echeverry R; Torre E; Haile WB; An J; Chen C; Cheng L; Nicholson A; Tong FC; Park J; Yepes M
    J Neurosci; 2014 Oct; 34(43):14219-32. PubMed ID: 25339736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. uPA-silica-Particles (SP-uPA): a novel analytical system to investigate uPA-uPAR interaction and to test synthetic uPAR antagonists as potential cancer therapeutics.
    Guthaus E; Bürgle M; Schmiedeberg N; Hocke S; Eickler A; Kramer MD; Sweep CG; Magdolen V; Kessler H; Schmitt M
    Biol Chem; 2002 Jan; 383(1):207-16. PubMed ID: 11930939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SLURP-1 modulates corneal homeostasis by serving as a soluble scavenger of urokinase-type plasminogen activator.
    Swamynathan S; Swamynathan SK
    Invest Ophthalmol Vis Sci; 2014 Aug; 55(10):6251-61. PubMed ID: 25168896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
    Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
    Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protein kinase C mediates up-regulation of urokinase and its receptor in the migrating keratinocytes of wounded cultures, but urokinase is not required for movement across a substratum in vitro.
    Ando Y; Jensen PJ
    J Cell Physiol; 1996 Jun; 167(3):500-11. PubMed ID: 8655604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physical association of uPAR with the alphaV integrin on the surface of human NK cells.
    Gellert GC; Goldfarb RH; Kitson RP
    Biochem Biophys Res Commun; 2004 Mar; 315(4):1025-32. PubMed ID: 14985115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subcellular distribution of urokinase and urokinase receptor in human neutrophils determined by immunoelectron microscopy.
    Pedersen TL; Plesner T; Horn T; Høyer-Hansen G; Sørensen S; Hansen NE
    Ultrastruct Pathol; 2000; 24(3):175-82. PubMed ID: 10914429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin.
    Kjøller L; Hall A
    J Cell Biol; 2001 Mar; 152(6):1145-57. PubMed ID: 11257116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.